GBA Presents: RADIO SAVANT-!

TravelCenters of America Non-GAAP EPS of $4.34 beats by $2.67, revenue of $3.08B beats by $120M
Aug. 01, 2022 4:24 PM ET TravelCenters of America Inc. (TA)
  • TravelCenters of America press release (NASDAQ:TA): Q2 Non-GAAP EPS of $4.34 beats by $2.67.
  • Revenue of $3.08B (+68.3% Y/Y) beats by $120M.
  • Shares +1.3%.
  • Adjusted EBITDA increased by 67% Y/Y. Fuel and non-fuel gross margins increased by 56% and 10%.
  • Capital expenditures for 2022 are expected to be in the range of $175M to $200M.
 
Bluebird Bio upgraded to Outperform at Raymond James following doctor survey 16:10 BLUE Raymond James analyst Dane Leone upgraded Bluebird Bio to Outperform from Market Perform with an $8 price target, stating that his survey of doctors suggest higher beti-cel utilization than anticipated. Beti-cel approval and launch in transfusion dependent beta-thalassemia, or TDT, could provide a "positive proxy" for lovo-cel adoption in sickle cell disease, or SCD, Leone tells investors.

I'm interested in this Co. BLUE IS GOING TO MURDER THE MARKET
 
Beti-cel and eli-cel from Bluebird Bio
Shares of Bluebird Bio (BLUE -7.41%) have been under a lot of pressure because the company spun off its revenue-generating cancer programs into a separate business called 2seventy Bio (TSVT -0.62%) last year. 2seventy Bio is already receiving modest royalties from its partner, Bristol Myers Squibb, on sales of Abecma, a recently approved cancer therapy.


BLUE.png

NASDAQ: BLUE
bluebird bio, Inc.
Today's Change
(-7.41%) -$0.30
Current Price
$3.75
BLUE
Key Data Points
Market Cap
$289M

2seventy's Bio's mama bird hasn't had a chance to flap its wings yet, but this could change in August or September. In August, the FDA is expected to issue an approval decision regarding beti-cel for the treatment of beta-thalassemia. And in September, the agency is set to announce its decision regarding eli-cel for the treatment of a rare disorder called cerebral adrenoleukodystrophy (CALD).

Beti-cel and eli-cel are gene therapies meant to provide a lifetime effect with a single administration. Sadly, this also means that any potential risks can't be mitigated by simply ceasing treatment. It looks like Bluebird Bio will be able to overcome this challenge. In June, FDA advisory committees unanimously agreed that the benefits of these two treatments outweighed the risks. The agency doesn't have to follow the advice of its independent expert committees, but they usually land on the same page.
 
I plan to add in size this month.

bluebird bio, Inc. (BLUE)
NasdaqGS - NasdaqGS Real Time Price.
3.7500-0.3000 (-7.41%)
At close: 04:00PM EDT
3.9100 +0.16 (+4.27%)<---- All day!
After hours: 05:00PM EDT
 
stonedinvestor said:
2- Karuna KRTX $131-----> $133---> $131--> $123.75 :caution: Turning into a big loser.[/B]
More...
I can't believe the Aug 19th $50 puts are $3.20 bid.
Someone actually sold 400 of them today

This thing is gonna move one way or the other Stoney

Two weeks ago

Insider Trading
Karuna Therapeutics Inc (NASDAQ:KRTX): A director purchases 120K shares at an average price of $122.80/share.

Athira Pharma Inc (NASDAQ
 
Karuna now hopes to build the case for its drug through two larger clinical trials — the first of which, named EMERGENT-2, should produce results by the end of September. The trial, which is evaluating nearly 250 adult patients with schizophrenia over a five-week period, finished enrollment this spring.

In a recent note, Jefferies analyst Chris Howerton wrote that his team puts the odds the trial succeeds at 75%. If KarXT goes on to secure FDA approval, Howerton claims it should have “no issue” surpassing $1 billion in annual sales.
:wtf::thumbsup::thumbsup::thumbsup:
 
You must log in or register to reply here.
Back
Top